ASX: EIQ **23 November 2026**

Leadership transition and appointment of Interim CEO

- **Mr Dustin Haines has tendered his resignation as CEO, effective 23 November 2026**
- **Executive Chairman, Mr Andrew Grover, to assume the additional role of Interim CEO**
- **Existing leadership team has extensive experience across key departments and provides a strong foundation for continued operational and commercial execution**
- **Recent appointment of Dr Vasum Peiris as Executive Vice President and Chief Medical Officer further strengthens the Company's clinical and strategic leadership**
- **Echo IQ remains well funded, having reported a cash balance of ~A$107m at the end of the September 2026 quarter**
- **Immediate priorities include advancing the US commercial rollout of FDA-cleared EchoSolv AS, progressing reimbursement pathways and reviewing the regulatory strategy for EchoSolv HF**

Sydney, Australia — Echo IQ Limited ("Echo IQ" or "the Company") (ASX: EIQ), a medical technology company developing AI-powered software for cardiovascular care, advises that Mr Dustin Haines has resigned as Chief Executive Officer (CEO) and as a director of its US subsidiary, Echo IQ, Inc., effective Monday, 23 November 2026. Following his resignation, Executive Chairman Mr Andrew Grover will assume the additional role of Interim CEO.

Mr Grover has been a director of the Company since 2019 and played a central role in its development, including previously serving as acting CEO from October 2021 to January 2025, prior to Mr Haines' appointment. During his tenure, he guided the Company's transition from a research and development-focused business to an FDA-cleared medical technology company with an expanding US presence.

Key milestones during Mr Grover's initial tenure as acting CEO included securing US Food and Drug Administration (FDA) clearance for EchoSolv AS in October 2024, establishing relationships with leading US healthcare institutions including Beth Israel Deaconess Medical Center, and strengthening the Company's financial position through institutional capital raisings. Mr Grover led the Company's previous capital raising initiative, securing the funding required to support its clinical development, regulatory milestones and expansion into the US market. As Executive Chairman, Mr Grover has also played a key role in the Company's strategic and clinical relationships, including with Pro Medicus Limited (ASX: PME) and Mayo Clinic.

Echo IQ remains in a strong financial position to advance its commercial roll out and regulatory objectives, with cash at bank of ~A$107 million as at 30 September 2026.

Mr Grover will be supported by the Company's strong and experienced leadership team which focus on key operational, clinical, technical and commercial functions. The individuals leading these departments provide continuity of operations and a solid foundation for the next stage of commercial growth. The team was recently strengthened by the appointment of Dr Vasum Peiris as Executive Vice President and Chief Medical Officer, adding to Echo IQ's executive leadership and clinical capabilities. Dr Peiris will play an important role in guiding the Company's clinical strategy, contributing to its regulatory strategy, supporting its commercialisation objectives and working alongside the existing leadership team to advance Echo IQ's position in the US healthcare market.

Mr Grover's immediate priorities will include advancing the US commercial rollout of FDA-cleared EchoSolv AS, progressing reimbursement pathways for the technology and determining the regulatory pathway for EchoSolv HF. This will be supported by a broader review of Echo IQ's operations and resource allocation to ensure alignment with its key commercial and regulatory objectives.

Alongside these priorities, the Company will continue to progress its broader clinical development activities and assess opportunities to strengthen operational efficiency.

Commentary:

Executive Chairman & Interim CEO, Mr Andrew Grover said: *"On behalf of the Board, I would like to thank Dustin for his leadership and contribution to Echo IQ. During his tenure, the Company has made important progress in strengthening its US operations, expanding its strategic relationships and establishing the financial and organisational foundations to support its next phase of development.*

Echo IQ has built a strong foundation, supported by an experienced and capable team leading each of our key departments. The appointment of Dr Vasum Peiris as Executive Vice President and Chief Medical Officer further strengthens our leadership team and brings valuable clinical and regulatory expertise as we move into the next phase of commercialisation.

With ~A$107 million in cash reported at the end of the September quarter, we are well funded to execute our strategy. Our immediate focus is on accelerating commercial execution in the US, progressing reimbursement for EchoSolv AS and establishing a clear regulatory pathway for EchoSolv HF.

We have a strong team, a solid financial position and significant opportunities ahead. I look forward to working closely with our people to execute our strategy and deliver long-term value for shareholders."

Mr Dustin Haines said: *"It has been a privilege to lead Echo IQ and work alongside a talented team committed to improving the diagnosis and treatment of cardiovascular disease. During my time with the Company, we have made meaningful progress in building our US presence, strengthening our partnerships and advancing the development of our technology.*

I'm proud of what the team has achieved and believe Echo IQ has an important opportunity ahead. Andrew has a deep understanding of the business and its strategic priorities, and I wish him, the Board and the team every success as the Company progresses its next phase of development."

There will be no change to Mr Andrew Grover's contract terms for taking on the role of Interim CEO. Mr Haines will receive his contractual entitlements under his executive services agreement.

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:
Andrew Grover, Executive Chairman & Interim CEO
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements, including statements about the Company's regulatory and commercial plans for EchoSolv AS and EchoSolv HF, reimbursement and leadership. These statements reflect the Company's current expectations and involve known and unknown risks and uncertainties, many outside the Company's control, including the outcome of FDA reviews. Actual results may differ materially. The Company does not undertake to update these statements except as required by law or the ASX Listing Rules. EchoSolv HF is not cleared by the FDA and is not available for commercial sale in the United States.